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ABSTRACT
Some biological aspects of the new complex imidazolium bisimidazole tetrachloro iridate(III)
IRIM- the iridium(Ill) analogue of ICR, were considered. More in detail the conformational effects produced
by IRIM on DNA and the cytotoxic properties of IRIM on some selected human cell lines were measured.
Dialysis experiments and DNA thermal denaturation studies are suggestive of poor binding of IRIM to DNA;
formation of interstrand crosslinks is not observed. In any case CD measurements suggest that addition of
increasing amounts of IRIM to calf thymus DNA results into significant spectral changes, that are diagnostic
of a direct interaction with DNA. A number of experiments carried out on the A2780 human ovarian carci-
noma, B16 murine melanoma, MCF7 and TS mammary adenocarcinoma tumor cell lines strongl point out
that IRIM does not exhibit significant growth inhibition effects within the concentration range 10"-10
"6 M. It
is suggested that the lower biological effects of IRIM compared to ICR are a consequence of the larger ki-
netic inertness of the iridium(Ill) center with respect to ruthenium(Ill).
INTRODUCTION
Following the success of cisplatin as an anticancer agent, new interest raised on the design and de-
velopment of new metal based antitumor agents 1,2]. Within this frame Keppler and coworkers prepared and
characterized a series of antitumor ruthenium(Ill) complexes, of which ICR (imidazolium bisimidazole tetra-
chloro ruthenate(III)) is probably the most representative [1]. Later on, Alessio and Sava developed NAMI A,
a compound structurally related to ICR, that has recently entered phase clinical trials [3]. The biological
evaluation of these innovative metal complexes has clearly pointed out that the mechanism of action of ru-
thenium compounds is substantially different from that of platinum complexes. Generally the direct cytotoxic
effects of ruthenium compounds are much lower than those produced by equimolar amounts of cisplatin
while the antimetastatic effects are more pronounced [3]. Also the direct DNA damaging effects are of much
lower intensity [4]. In this context it is of interest to evaluate the biological effects of isostructural metal
complexes, obtained by simple replacement of the central metal ion. The comparative analysis of the phar-
macological profiles provides information on the specific role ofthe metal. Ruthenium(Ill) complexes may
be easily mimicked by rhodium(Ill) complexes and iridium(Ill) complexes. Some studies already appeared
on the rhodium(Ill) analogue of ICR [5]; the iridium(lII) analogue of ICR-IRIM- has been recently synthe-
sized by Mura [6].
IRIM
c/ c
Figure Schematic drawing of the imidazolium bisimidazoletetrachloroiridate(lll)-IRIM-complex.
The most striking difference between ICR and its rhodium and iridium analogues consists in the increasing
kinetic inertness of the metal center. In this study we report on some significant biological properties of
IRIM. More specifically the effects of IRIM on DNA stability and conformation in solution and its cytotoxic
properties toward a number ofhuman tumor cell lines were investigated.
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MATERIALS AND METHODS
IRIM was synthetized as reported [6]. The purity of the compound was checked through elemental
analysis and H NMR spectroscopy. Calf thymus DNA was purchased from Sigma Chemical Company. All
other reagents used in this study were of analytical grade and were commercially available.
Electronic absorption spectra were measured with a Perkin Elmer Lambda 20 Bio instrument.
Electronic spectra of IRIM 3.6x10
.4 M were recorded before and after addition of calf thymus DNA
(r 0.7) in the phosphate 50 mM, NaC1 4 mM, pH 7.4 buffer and the same sample was dialyzed after 24h in-
cubation. The spectra of the upper portion of the solution containing calfthymus DNA and of the lower por-
tion of the solution, containg only the iridium(Ill) complex, were recorded.
All melting measurements were carried out in the 10
.2 M NaCIO4 and 10
.3 M NaCI buffer. Calf thy-
mus DNA was dissolved in the buffer and DNA concentration determined by absorption measurements at
260 nm. DNA concentration was equal to 3.6x10
5 M [nucleotide]. DNA was treated with IRIM at different
mol/bp ratios (r 0.01, 0.1, 1.0)and each sample was incubated for 24 hrs at room temperature.
Thermal denaturation experiments were performed in quartz cuvettes with a Perkin Elmer Lamba 20
Bio spectrophotometer equipped with a thermostated cell as described in reference. Samples were continu-
ously heated with a rate of temperature increase of 0.5C/min while monitoring the absorbance changes at
260 nm. The investigated interval of temperature ranged from 50C to 90C. Upon reaching 90C, samples
were cooled back to 40C in order to follow the renaturation process. Values for melting temperatures (Tin)
and for the melting interval (AT) were determined according to the reported procedures [7].
CD spectra were recorded at increasing IRIM/calf thymus DNA ratio (r= 0.0, 0.01, 0.1, 1.0) after
mixing on a Jasco J600 dichrograph operating at room temperature, interfaced with a PC, and analyzed
through the standard Jasco software package.
Cytotoxicity measurements were carried out on the A2780 ovarian carcinoma cell line, both sensi-
tive and resistant to cisplatin (A2780/S and A2780/R) following the Sulphorhodamine-B (SRB) procedure
[8], and data analyzed through standard methods. Cells were exposed to the cytotoxic agent for 72 hours.
The activity of IRIM on the B16 melanoma, MCF7 breast cancer and TS adenocarcinoma tumor cell
lines was also analyzed, upon treatment 24 or 72 hours long. Cell growth of samples treated with increasing
concentrations of IRIM -10 M, 10" M and 104M- was monitored in comparison to controls through the mi-
croculture tetrazolium test (MTT) [9] or SRB method [8].
Figure 2 Electronic spectra of IRIM (a) 3.6x1074 M following addition of calfthymus DNA r 0.7 (b)
in phosphate buffer 50 mM, NaCI 4 mM, pH 7.4.
RESULTS
Interactions oflRIM with calfthymus DNA
The interactions of IRIM with calf thymus DNA in vitro was first analyzed by visible spectroscopy.
As previously reported [6], IRIM is soluble in a physiological buffer and gives rise to a characteristic absorp-
tion spectrum in the visible. Notably, the visible spectrum of IRIM does not change over a period of several
hours, at room temperature, implying that the metal chromophore is relatively stable under physiological
conditions [6]. In order to monitor the reaction of IRIM with DNA, the visible spectra of IRIM were recorded
following addition of saturating amounts of calfthymus DNA. Notably the presence of DNA does not affect
significantly the visible spectrum of IRIM implying that the metal chromophore is substantially conserved.
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On the other hand ultradialysis experiments are suggestive of weak binding of IRIM to calfthymus
DNA: either the fraction containing calfthymus DNA or the DNA-free fraction contain comparable amounts
of IRIM following ultrafiltration.
The effects that IRIM produces on the structure and conformation of calfthymus DNA were further
investigated through circular dichroism and DNA melting studies, The CD technique is indeed extremely
sensitive to the conformation of DNA double helix. CD spectra of calf thymus DNA upon addition of in-
creasing amounts of IRIM are shown in Figure 3,
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Figr 3 Circular diehroism spectra of calfthymus DNA upon addition of increasing amounts of
IRIM. Spotrawr roordd at the following r values: 0.0, 0.01, 0.1 ad 1.0 (from top to bottom at 260 nm).
Conditions: phosphate 50 mM, NaC1 4 mM, pH 7.4 buffer, calf thymus DNA 3.6x10"s M (basepair concen-
tration).
It is observed that IRIM affots somehow th CD spotm of DNA, Th ffeots are of larger inten-
sity as th ratio IRIM/ealf thymus DNA is inorased from 0.01 to 0.1 ad to 1. A progressive deorease of
the positive band at 275 nm and of the negative one at 240 nm is observed, with an isosbestic point at 260
rim. This observation suggests that addition of inorasing amounts of IRIM induos a oonfoational transi-
tion ofcathymusNA within the frame of a B-type eonfoation.
Theal denaturation profiles ofea thymus DNA were investigated in the presence of inoreasing
amounts of IRIM" th sam patt of IRIM oonoentrations of the CD studies was investigated (0.01, 0.1
and 1.0). A representative complete melting profile (heating and cooling process) is shown in Figur 4 and
the rlvant parameters xtraotd from th individual experiments ar rpoed inTI 1.
Table 1 Experimental Tm (C), AT (C) and AH values as determined from the thermal denaturation profiles
of calfthymus DNA and of the adducts IRIM/calfthymus DNA at the ratios 0.01, 0.1 and 1.0; data on the ad-
ducts ICR/calfthymus DNA (r=0.01 and 0.1) are shown.
Calfthymus DNA
iRIM/ctDA r--0.01
IRIM/ctDNA r--0.1
IRIM/ctDNA r=l
ICR/ctDN r=0.0!
ICR/ctDN r=0.1
Tm (C) AT (C)
67.63
67.05
67.50
67.00
66.70
67.50
10.80
9.98
9.88
11.43
11.60
9.90
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Figure 4 Denaturation (a) and "renaturation" (b) profiles of calf thymus DNA 3.6x10
5 M as col-
lected by melting measurements.
It clearly emerges that addition of increasing amounts of IRIM does not affect significantly the
melting temperature of calfthymus DNA. In other word there is no evidence of stabilization or destabilization
of the double helix following IRIM addition. It can just be observed that at the highest ratios the AT value is
slightly increased. The DNA renaturation profiles show that the presence of IRIM does not favor at all the
strand pairing process after melting, ruling out that IRIM is able to induce formation of interstrand crosslinks.
Cytotoxic effects oflRIm
The cytotoxic properties of IRIM in vitro were evaluated through two distinct experiments. They
were first analyzed on the A2780 ovarian carcinoma cell line either sensitive or resistant to cisplatin in com-
parison to ICR and CDDP. Results are shown in Table 2.
It clearly emerges that IRIM produces a very modest growth inhibition effect; ICs0 values larger than
150 ktM were estimated on the cisplatin sensitive line to be compared with values of 80 laM for ICR and 2
[aM for cisplatin. Far larger ICs0 values for all complexes, within the same order of cytotoxic potency, were
found in the case of the cisplatin resistant line A2780/R.
Table 2 IC50 values (M) of cisplatin-sensitive and-resistant human tumor cell lines [A2780/S and A2780/R
of ovarian carcinoma] towards IRIM and ICR. For comparison purposes the values obtained with CDDP are
reported. The values reported in this table are the average_+ SE of 3 experiments for IRIM, the average of 2
experiments for ICR and the average_+ SE of 5 experiments for CDDP.
IRIM
ICR
CDDP
A2780/S
1.67.5-+46.9
80
1.6-+0.58
A2780/R
>480
>240
16.1-+3.85:
exp. n.
Later on, the cytotoxic effects of IRIM were monitored on the following human tumor cell lines: B I6 mela-
noma, MCF7 breast cancer and TS adenocarcinoma. Cell growth of samples treated with increasing concen-
trations of IRIM 106M, 10SM and 104M was monitored in comparison to controls through the MTT or
SRB methods. Again no significant difference was detected among treated samples and controls, pointing out
that the inhibitory effects of IRIM are indeed very poor.
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Figure S Cytotoxic activity of IRIM towards the B16 murine melanoma cell line, MCF7 and TS
mammary., adenocarcinoma cell lines (after 24 or 72 hours treatment). IRIM had three different concentrations
(10"6, 10
.5 e 104M); vitality was measured following the MTT and SRB procedures. The values reported in
this graphs are the average+ SE of 3 experiments.
DISCUSSION
Metal complexes other than platinum are today actively investigated as potential cytotostatic and
antitumor drugs. In this frame, much work has been devoted to the analysis of ruthenium(III) complexes that
showed in some cases promising biological and pharmacological profiles. A ruthenium(III) complex- NAMI
A- is presently undergoing phase clinical trials. Structural analogues of ruthenium(III) complexes may be
prepared by using rhodium(III) or iridium(III) as the central metal/on. We are exploiting iridium(III) ana-
logues of known antitumor ruthenium(III) complexes as novel antitumor agents; the aim is to define the
chemical and biological consequences resulting from the replacement of the ruthenium(III) center with the
more inert iridium(III) center.
In this paper we report on the biological behaviour of IRIM, trans bisimidazole tetrachloro iri-
date(III), compared to ICR. Specifically two aspects of the pharmacological behaviour of IRIM have been
stressed: i) the interaction with DNA; ii) the cytotoxic effects on a number ofhuman tumor cell lines.
i) The interaction with DNA
DNA was selected since it represents a major target for platinum(II) antitumor compounds and is the
probable target for several other antitumor metal complexes. The interaction of IRIM with calfthymus DNA
was monitored through a number of classical screening techniques including circular dichroism, analysis of
DNA thermal denaturation and dialysis experiments. This approach permits to establish whether i) the metal
chromophore undergoes transformations upon binding; ii) the conformation of DNA is modified; iii) the
double helix is stabilized, destabilized or unaffected; iv) interstrand crosslinks are formed.
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Overall, IRIM produces modest effects on DNA in the sense that the metal chromophore is virtually
unaffected by addition of DNA; the stability of the double helix is only weakly decreased even at the highest
ratios; formation of interstrand crosslinks is not observed. Some evidence of interaction is obtained from CD
spectra indicating the occurrence of slight conformational changes of the DNA solution structure. A possible
interpretation of these results stems on the fact that IRIM is far less reactive than ICR since ligand exchange
reactions are much slower. In the case of ruthenium(III) complexes like ICR and NAMI, it is assumed that
reactions with biologically relevant targets take place following chloride hydrolysis. It is straightforward to
hypothesize that IRIM does not form coordinative bonds with DNA since it is not able to hydrolyze to a sig-
nificant extent under physiologically occuring conditions. The only type of reactivity with DNA that can take
place in the absence of hydrolysis is some groove interaction. In the light of the present results, it can be
stated that IRIM exhibits very modest DNA modifying properties.
ii) The cytotoxic properties.
The lack of DNA modifying properties does not necessarily imply that IRIM must be discarded a
priori from any further pharmacological evaluation. Indeed, apart from DNA binding, other mechanisms can
be responsible for the antitumor activity, such as binding to proteins involved in DNA methabolism or impli-
cated in malignant transformation and maintenance of the transformed phenotype. With this in mind, we fur-
ther tested the biological properties of IRIM by analyzing its cytotoxic properties toward selected human tu-
mor cell lines. Four major lines were considered, namely A2780 ovarian carcinoma, B16 melanoma, MCF7
breast cancer and TS adenocarcinoma tumor cell lines. We found that IRIM shows very modest cell growth
inhibition effects. The comparison with cisplatin is striking: on the A2780 line the ICs0 value of cisplatin is 2
laM, that of IRIM is 140 laM; nevertheless, it is worthwhile noting that the ICs0 value of ICR on the same cell
line is 80 tM, close to that of IRIM. Indeed the cytotoxicity test has been longly considered and it must be
stressed that many compounds with good tumor cell-killing activity have been discovered, but few have
found clinical utility. On the other side, in recent years, several non cytotoxic compounds- among which
some ruthenium(III) complexes turned out to exhibit relevant anticancer properties. Thus, we must ap-
proach the cytotoxicity test considering the following limits: 1) a lack of discrimination between effects on
tumor and normal tissue, 2) the cell-cycle dependency of many cytotoxic drugs and 3) the frequent suscepti-
bility of these substances to induced drug resistance. To conclude, in our opinion, before stating that IRIM
and similar iridium(III) complexes are not useful as antitumor agents, it is necessary to perform more ad-
vanced in vitro and in vivo pharmacological studies.
CONCLUSIONS
In vitro interactions of IRIM with calf thymus DNA were analyzed through various physico-
chemical techniques. It is found that IRIM induces small conformational changes on DNA. Overall the ob-
served effects are much weaker than those induced by cisplatin. Notably DNA modifications brought about
by ICR are larger than those produced by IRIM. It is hypothesized that the interaction of IRIM with DNA is
essentially non-covalent in nature whereas ICR is able to form coordinative bonds. The weak DNA modify-
ing properties correlate with low cytotoxicity on a number ofhuman tumor cell lines.
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